Izadi, Mahmoud
Sadr Hashemi Nejad, Anavasadat
Moazenchi, Maedeh
Masoumi, Safdar
Rabbani, Ali
Kompani, Farzad
Hedayati Asl, Amir Abbas
Abbasi Kakroodi, Fatemeh
Jaroughi, Neda
Mohseni Meybodi, Mohammad Ali
Setoodeh, Aria
Abbasi, Farzaneh
Hosseini, Seyedeh Esmat
Moeini Nia, Fatemeh
Salman Yazdi, Reza
Navabi, Roghayeh
Hajizadeh-Saffar, Ensiyeh
Baharvand, Hossein http://orcid.org/0000-0001-6528-3687
Clinical trials referenced in this document:
Documents that mention this clinical trial
Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial
https://doi.org/10.1186/s13287-022-02941-w
Documents that mention this clinical trial
Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial
https://doi.org/10.1186/s13287-022-02941-w
Funding for this research was provided by:
Royan Institute (94000019)
Iranian Vice-Presidency for Science and Technology, Council for Development of Stem Cell Sciences and Technologies (REP-441)
Article History
Received: 19 September 2021
Accepted: 4 June 2022
First Online: 20 June 2022
Declarations
:
: The Research Ethics Committee at Royan Institute approved this study (approval code: IR.ACECR.ROYAN.REC.1394.50), and the study was conducted under the Declaration of Helsinki. All participants or their parents or legal guardians (when required for pediatric participants) received comprehensive oral and written information about the nature and possible consequences of the study. They signed a written informed consent form before participating in this clinical trial.
: Not applicable.
: The authors declare that they have no competing interests.